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ABSTRACT 
Background: - Dracaena Cinnabari  balf is a species plant in Agavaceae family. It is 
a tree endemic to the Island of Socotra,Yemen .It was used as a dye and medicine in Socotra  
and the Mediterranean basin. Some researches demonstrated both hypoglycemic and 
hypolipidemic of its resin of Dracaena Cochinchinensis, a traditional Chinese tree. 
Accordingly, this study aimed to evaluate the antidiabetic potential of the ethanolic extract of 
dracanea cinnabari balf resin (DCBR), endemic in Socotra Island, in Alloxan induced 
diabetes, and evaluation of possible antihyperlipidemic activity of the same extract in high-
cholesterol diet-induced hyperlipidemia in male albino rats. 
Methods: - Experimental diabetes was induced in rats with intraperitoneal injection a single 
dose of Alloxan (150 mg/kg). Hyperlipidemia was induced in rats by administration of 1% 
cholesterol in diet and 0.5 % Hydrogen Peroxide in drinking water for 14 days. Fasting blood 
glucose levels were measured at 1st day, 7th day and 14th day. Pancreas histopathology was 
done at the end. Estimation of serum lipid profile and liver   histopathology was done at the 
end of 14 day. The results were expressed as mean ± SD and differences among the groups of 
animals were compared using one-way ANOVA. 
Results:- Administration of ethanolic extract of  resin of two doses (100mg and 300mg\kg) in 
alloxan  induce diabetic rats resulted in a significant decrease in FBG levels with a recovery 
in destruction of pancreas cell compared with untreated group .Also the same doses of extract 
showed significant decrease in triglycerides ,total cholesterol ,low density lipoprotein, very 
low density lipoprotein and alkaline phospatase in comparing with untreated groups. 
Conclusion: - From the results of present study we can conclude the ethanolic extract of 
Dracaena cinnabari Balf. have a hypoglycemic and hypolipidemic activity in experimental 
animals  , these activity are time and dose dependent.    
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Introduction: 
Diabetes mellitus is a group of metabolic disorders characterized by elevated levels of 
glucose in blood (hyperglycemia) due to insufficient production of insulin or because cells do 
not respond to insulin produced [1]. It is estimated that about 350 million people have 
diabetes, the prevalence being similar in both high and low income countries and it is 
forecasted that global diabetes prevalence will increase by 50% in 2030 [2].  
The disease is characterized by increase production of oxygen–free radicals such as 
superoxide (O2
-
), hydrogen peroxide (H2O2), and hydroxide (OH
-
) radicals and lack in 
antioxidant defense mechanisms which lead to increase oxidative stress and development of 
diabetes complications [3]. Management strategies of diabetes include life style intervention 
through diet modification and exercise and the use of oral hypoglycemic therapy and insulin 
treatment [4]. 
Hyperlipidemia related to increased oxidative stress causing significant production of 
oxygen free radicals, which may lead to oxidative modifications in low-density lipoproteins, 
  
which present a significant function in the initiation and progression of atherosclerosis and 
associated cardiovascular diseases[5].  
The treatments for hyperlipedemia vary according to factors that include heart disease 
risk, lipid levels and a patient's overall health. Potential treatments for lipid disorders include 
dietary changes, weight loss, regular exercise, quitting smoking, medications and periodic 
lipid screenings [6].  The chemical drugs used for treatment of hyperlipidemia are :statin, 
fibrates, In addition, other drugs, such as ezetimibe, colesevelam, torcetrapib, avasimibe, 
implitapide, and niacin are also being considered to manage hyperlipidemia [7]. 
Although the drugs are available in the market, long term use may cause a number of 
side effects. Hence a large number of studies is in progress to find natural sources, which are 
effective in reducing the intensity of diabetes and hyperlipidemia. World Health Organization 
(WHO) approved the use of plant drugs for different diseases [8] including diabetes mellitus 
[9] and hyperlipidemia  [10]. One of these plants is Dracanea cinnabari, known as Dam Al 
Akhawain, It is one of the rare and blessed tree in islet of Socotra, Yemen. 
Dracaena Cinnabari  balf is a species plant in Agavaceae family. It is a tree endemic 
to the Island of Socotra,Yemen [11] the evocatively named dragon’s blood tree has a unique 
and bizarre appearance, its upturned, densely-packed crown having the shape of an upside-
down umbrella[12].  
The name Dracaena is derived from the Greek word ‘drakainia’ meaning a female 
dragon). The most striking source is the Dracaena cinnabari Balf. f. which is endemic to the 
island of Socotra (Yemen) [13]. There are a lot of reaserches that have been worked on 
Dracena cinnabari balf resin and approved its effectiveness as antimicrobial,antiviral [14], 
Antitumor and cytotoxic [15]. It is also found that, it is a potent  analgesic [16], Antioxidant 
[17] and anti-inflammatory[18].  
No previous studies about in vivo antidiabetic and antihyperlipedimec activity of Dracaena 
Cinnabari  balf resin that is a species plant endemic to the Island of Socotra, Yemen. 
Accordingly, the current study was done to prove the antidiabetic and antihyperlipedimec 
activity of Dracaena Cinnabari  balf resin ethanolic extract in experimental animals . 
Methods  
Chemical and Instruments 
ALLOXAN 98% (Hydrate) which was obtained from Oxford laboratory, India. 
Glibenclamide which obtained from DSM Sinochem pharmaceuticals, India. Auto analyzer 
performa- accuCheck Advantage II, Roche), Glucose kit from Roche, Germany. Cholesterol 
powder obtained from BDH chemicals LTD, England. Atorvastatin which obtained from 
DSM  Sinochem pharmaceuticals, India. Hydrogen peroxide 30% obtained from EMPLURA 
(500ml) MERCK, India. Cholesterol. Triglyceride, HDL and LDL kits. HumaLyzer3500 
photometers, Germany. 
Plant material 
Dracaena cinnabari balf resin is exuded and collected from incisions of the trunk of 
Dracaena cinnabari Balf.. 
Preparation of ethanolic extracts  
One kilogram of the Resin was washed thoroughly with distilled water, air-dried, powdered 
with an electrical grinder, and soaked in 99% ethanol (1:10) at room  temperature (25C°) 
over period of 48 hr and were shaken several times(maceration  method). The ethanol 
containing the extract was then filtered through Whitman paper then  the solvent was vacuum 
distilled at 40 C° in rotary evaporator. Final extract was red semi-solid in percentage dry 
weight 90%. This ethanol extract was kept at 4C° until use. 
Experimental animals: 
  
Healthy male albino rats of Wistar strain weighing 150-250g.They were obtained from the 
Central Animal House, Sana’a University. The present study was approved before start off 
experiment by the animal Ethics committee, 00243,Goverment of Yemen constituted, Sana’a 
university. The animals were housed in standard polypropylene cages and maintained within 
the same room temperature and humidity with 12:12 hour light and dark cycle. All the rats 
were given a 14-day period of acclimatization before starting the experiment. 
 Induction of diabetes : 
Diabetes was induced by intraperitoneal administration of a single dose of 
alloxan(150 mg/kg) [20]. Male albino rats   were fasted for 18 h. The fasting blood sugar 
(FBS) levels of the rats were  determined with blood from the rats’ tail vein using an auto  
analyzer (AccuCheck Performa Advantage II, Roche).Freshly prepared Alloxan monohydrate 
dissolved in normal saline (0.9% w/v NaCl) and injected as a single dose of 150 mg/kg 
intraperitoneally  to induce hyperglycemia. To avoid fatal hypoglycemia as a result of 
massive  pancreatic insulin release, rats were  Kept for the  next 24 h on 5% glucose [21] . 
After 72 hours, rats with fasting blood glucose Level more than 250 mg/dL were considered 
to be diabetic and  selected for studies  [22]. The experiment was approved by the 
Institutional Ethical Committee, Faculty of Medicine and Health Sciences, Sana`a University. 
Experimental design:  
Evaluation of antidiabetic activity of DCBR methanolic extract in alloxan –induced 
diabetic rats . 
The  albino rats were allocated  randomly into five groups, each containing six rats :- 
Group 1: Normal control, without treatment rats.  
Group2: Diabetic control, without treatment rats  
Group3: Diabetic rats  received  Ethanolic extract (100 mg/kg/day, p.o  [23]  
Group4: Diabetic rats  received  Ethanolic extract (300 mg/kg/day, p.o.) [23]  
Group5: Diabetic rats  received glibenclamide (2.5 mg/kg/day, p.o.)  [24]  
After 72 hours from administration  of alloxan  rats with hyperglycemia more than 250 mg\dl 
were selected and used for experiment . The rats were administered the extract (dissolved in 
Tween 80) and chemical drug for two weeks orally by using a feeding cannula. 
The experimental rats were weighed every day to compare the body weight change in 
different groups through the experimental period. FBG was estimated before the start of 
treatment ,on 7
th
 day and 14
th
  days of treatment . All rats were later sacrificed on 14th days 
by diethyl ether and the Pancreases were weighted separately then collected in10 % formalin 
for histopathological examination.  
Histopathological examination of Pancreas: 
For histological study, specimens of pancreases were immersed in neutral buffered 
formalin (10%) for 48 hours. Then tissue dehydration was done using ascending grades of 
alcohol (ethanol), followed by tissue clearing using xylene. The tissues were transferred to 
molten paraffin for impregnation and embedded in paraffin blocks. After fine sectioning, 
staining was done using hematoxylin and eosin (H and E) stain and examined under a 
microscope [25].  All the sections were examined under a light microscope under X400 
magnifications. Photomicrographs of lesions were taken for observations and documentation 
of histopathological lesions. 
 Induction of hyperlipidemia: 
Hyperlipidemia was induced in rats by administration of 1% cholesterol in diet and 0.5 % 
Hydrogen Peroxide in drinking water for 14 days [26]. 
Experimental design : 
Evaluation of antihyperlipidemic activity of DCBR methanolic extract in experimental 
rats. 
The  albino rats were allocated  randomly into five groups, each containing six rats :- 
  
Group 1: Normal control, without  treatment. 
Group 2: (Hyperlipidemic rats)  received 1% cholesterol + 0.5 % Hydrogen Peroxide  
Group 3: (Hyperlipidemic rats) received 1% cholesterol + 0.5 % Hydrogen Peroxide and  
Ethanolic extract (100 mg/kg/day, p.o)   
Group 4: (Hyperlipidemic rats ) received 1% cholesterol + 0.5 % Hydrogen Peroxide and  
Ethanolic extract (300 mg/kg/day, p.o)  
Group 5: (Hyperlipidemic rats ) received 1% cholesterol + 0.5 % Hydrogen Peroxide and  
Atorvastatin (10 mg/kg/day, p.o)[27]   
After experimental period, and after an overnight fasting, animals in different groups 
were anesthetic under mild diethyl ether and the blood was withdrawn by retro-orbital 
method to determine serum lipid profile. Serum obtained by immediate centrifugation of 
blood samples using centrifuge at 3000 rpm for 15 min. at room temperature. The 
concentration of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) and 
low-density lipoprotein (LDL) was determined by using enzymatic commercial kits marketed 
by QCA Ltd, Spain. While VLDL and atherogenic index in plasma was calculated as per 
Friedewald estimation[28] . Then, the animals were sacrificed to take the liver and aorta 
specimens for histopathological examination. 
Histopathological examination of liver and Aorta: 
Specimens of liver and aorta were immersed in neutral buffered formalin (10%) for 
48 hours. Then tissue dehydration was done using ascending grades of alcohol (ethanol), 
followed by tissue clearing using xylene. The tissues were transferred to molten paraffin for 
impregnation and embedded in paraffin blocks. After fine sectioning, staining was done using 
hematoxylin and eosin (H and E) stain and examined under a microscope [25]. All the 
sections were examined under a light microscope under X400 magnifications. 
Photomicrographs of lesions were taken for observation and documentation of 
histopathological lesions. 
 
Statistical analysis: 
The result were expressed as mean ± SD and differences among the groups of animals were 
compared using one-way ANOVA with post-hoc LSD's test. Statistical significance was set 
at P ≤ 0.05. Statistical analysis was performed using Microsoft excel, and SPSS software 
version 20. 
 
RESULTS: 
Result of antidiabetic activity of DCBR methanolic extract in alloxan –induced diabetic 
rats. 
 Relative change in body weight: 
Measurement of the weight of all animals from the first day to the last day of the 
experiment showed an irregular change and differences in the groups as shown in Table (1). 
The weight of group 1 increased significantly from 1st day to 14th day in opposite to group 2. 
While, the groups that treated  with 100 mg/kg (group 3) and 300 mg/kg DCBR extract 
(group 4) showed noticeable improvement to normal weight during treatment period whereas 
the weight were dropped dramatically because of Alloxan injection. Group 5 that was treated 
with 2.5 mg/kg Glibenclamide kept the same weight level during treatment period. 
 
 
 
  
 
 
 Relative change in weight of pancreas: 
As shown in table (2), after 14 day of treatment, there was a significant decrease in 
pancreas weight in group 2, in comparison to group 1 (p-value≤ 0.05). Group 3 which was 
treated with 100 mg/kg DCBR extract showed an increase in pancreas weight. We got the 
same result with group 5 which was treated with 2.5 mg/kg Glibenclamide, whereas group 4 
which was treated with 300 mg/kg DCBR extract, showed a significant increase in the 
pancreas weight in comparison to group 2 
Table (2): The effect of DCBR extract on change in the pancreas weight (g) of Alloxan -
induced diabetic rats; n=6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biochemical investigation (FBG): 
The groups 2, 3, 4 which were injected with 150mg/kg alloxan showed a significant 
increase in the FBG values more than 200mg/dl (p-value ≤ 0.05) in comparison to group1. 
After 7days of treatment , the dose of 100 mg/kg DCBR extract(group 3) , 300 mg/kg DCBR 
extract(group 4) and 2.5 mg/kg Glibenclamide (group 5) showed a significant change in 
comparison to group 1 and group 2 (p- value ≥ 0.05) , as well as after 14 days of treatment. 
By the way, group 4 did not show a significant change in FBG in comparable to group 1, 
Table (1):  The effect of DCBR extract on change in the body weight (g) of Alloxan -
induced diabetic rats. ;n=6 
Groups 1
st
  Body weight(g) 7th day Body weight(g) 14
th
 day Body weight(g) 
 
Group 1 165.41±43.8 196.46±32.7 219.5±35.7 
Group 2 178.33±17.4 158.66±32.3 146.73±36.3* 
Group 3 175.93±25.7 184.48±26.5 196.05±27.5 
Group 4 153.16±43.1 172.28±40.5 187.73±39.0 
Group 5 153±14.0 150.56±19.9 150.03±18.5* 
Values are expressed as Mean ±SD; *P ≤ 0.05 vs. group 1. DCBR: Dracanea cinnabari  
balf  Resin.  
Groups pancreas weight (g) mean ±SD 
% of change  vs. group 
1 
Group 1 1.57±0.43  
Group 2 0.48±0.08* 69.4 % 
Group 3 1.03±0.42 34.3% 
Group 4 1.33±0.43** 15.3% 
Group 5 0.92±0.21* 41.4% 
Values are expressed as Mean ±SD; *P ≤ 0.05 vs. group 1, **P ≤ 0.05vs. Group 2. 
DCBR: Dracanea cinnabari  balf  Resin.  
  
which means that 300 mg mg/kg DCBR extract dose, achieved the target normal value of 
FBG.  Table (3) 
 
 
Histopathological examination of pancreas: 
 Macroscopic observations : 
The pancreas was subjected to macroscopic and microscopic investigation to detect 
irregularities and abnormalities of the structure .Macroscopic analysis of the control group 
demonstrated normal pinkish appearance (Fig.1a) in comparison to the pancreas of untreated 
diabetic, depletion large area of the pancreas as a result of alloxan injection 150 mg/kg, 
(Fig.5c). Treated groups with 300 mg/kg extract , 100 mg/kg extract ,and 2.5 mg/kg 
Glibenclamide showed clear preserved tissue(Fig. 1e, 1g, 1i) respectively). 
 Microscopic observations : 
The microscoic appearance of the control group islet cells (group 1) was normal (Fig.5b). 
Untreated diabetic group (group2) revealed a breakdown of micro-anatomical features 
including necrosis as in (Fig. 1d). The comparison of the untreated diabetic group to normal 
group, there was a destruction in the islet cells with irregular shape and atrophy (Fig. 1d).  
(Fig. 1f, 1h, 1j) figures showed treated diabetic rats with 100 mg/kg extract (group 3), 300 
mg/kg extract (group 4) and 2.5 mg/kg Glibenclamide (group 5) respectively. The 
comparison of these three groups with the untreated diabetic rats, there was an evidence of 
recovery of langerhans islets, more obvious islet pattern with well outlined boundaries, 
vacuolation was reduced or absent in many islets.   
 
Result of antihyperlipidemic  activity of DCBR methanolic extract in experimental rats. 
 Relative change in body weight: 
Based on the result reflected on table (4), we could say that the rats of groups 2,3,5 
(hyperlipidemic without treatment, 100 mg/kg DCBR extract, 10 mg/kg Atorvastatin 
respectively, showed an increased growing in body weight throughout the entire period of 
Table (3): Effects of DCBR extract on the FBG values (mg/dl) of Alloxan-induced diabetic rats; n=6 
 Groups 
Basal 
Value(mg/dl) 
7
th
 day(mg/dl) 
%of  FBG 
change vs. 
Basal Value 
after 7 days 
14
th
 day(mg/dl) 
%of  FBG 
change vs. 
Basal Value 
after 14 day 
Group 1 80.16 ±9.7 88.16±4.2   90.3±6.7   
Group 2 495.0±32.7* 522.16±31.1 *
, ∆
   508.4±34.9*
, ∆
   
Group 3 381.6±22.2*
,
** 291.8±18.1 *
,
**
, ∆
 24% 180.8±14.9*
,
**
, ∆
 53% 
Group 4 473.6±14.7* 186.6±4.4*
,
**
, ∆
  60.5% 101.6±3.1**
 , ∆
 79% 
Group 5 481.5±11.4* 415.0±13.7*
,
**
, ∆
 14% 217.0±10.7*
,
**
, ∆
 55% 
Values are expressed as  Mean ±SD ; *P ≤ 0.05 vs. group 1for each column, **P ≤ 0.05  vs. group 2 for 
each column.
 ∆P ≤ 0.05 vs. basal value for each row.  DCBR: Dracanea cinnabari  balf  Resin, FBG: 
Fasting Blood Glucose.  
  
treatment. However, there was a decrease in group 4 which was treated with 300 mg/kg 
DCBR extract. All changes was statistically insignificant (p- value ≥ 0.05). 
 
Table (4): The effect of DCBR extract on change in the body weight (g) of 
hyperlipidemic rats; n=6 
Groups Initial Body weight (g) 7
th
 day body weight (g) 14
th
 day Body weight (g) 
Group 1 251.33±22.5 271.48±19.7 295.01±15.5 
Group 2 277.9±6.6 279.25±2.1 287.3±0.6 
Group 3 295.4±32.1 293.4±34.2 305.46±32.6 
Group 4 321.3±43.3 279.41±37.5 280.98±42.4 
Group 5 306.53±35.9 300.26±30.4 316.38±34 
Values are expressed as Mean ±SD;*P ≤ 0.05 vs. group 1. DCBR: Dracanea cinnabari  
balf  Resin. 
  
 Relative change in weight of liver: 
As shown in table(5), after 14 day of treatment ,there was a significant change in the liver 
weight of group 2 in comparison to group 1 (p-value≤ 0.05). also, other three groups of 
treatment with 100mg/ kg DCBR extract (group 3), 300 mg/ kg DCBR extract (group 4)and 
10 mg/kg Atorvastatin (group 5) showed a significant change and decrease  the liver weight 
in comparison to group2 (p-value≤ 0.05)  
 
 Biochemical parameters: TC, TG ,HDL,LDL, VLDL, and  AI: 
As in table (6) the rats when fed with high-fat diet (1% cholesterol) showed a 
remarkable hyperlipidemia. For the whole group, there was a signiﬁcant increase in TC, TG, 
LDL, VLDL Al, and a decrease in HDL in comparison to group1 (p-value≤ 0.05). When we 
compare the treated groups with group 2, we noticed that: the treated group with 100 mg/kg 
DCBR extract(group 3) showed a significant decrease in TC, TG, LDL,VLDL and AI and a 
significant increase in HDL (p-value≤ 0.05), (where the change in TC,TG,LDL was 
insignificant, and VLDL was significant) .The higher dose of 300 mg/kg DCBR extract 
Table (5): The effect of DCBR extract on change in the liver weight (g) of 
hyperlipidemic rats; n=6 
Groups liver weight (g) 
mean ±SD 
% of change vs. group 1 
 
Group 1 9.65±0.25  
Group 2 16.9±0.91* 43% 
Group 3 10.4±1.08** 7.8% 
Group 4 11.13±1.09** 13% 
Group 5 13.21±2.36*
&
** 27% 
Values are Mean ±SD; *P ≤ 0.05 vs. group 1, **P ≤ 0.05  vs. group 2.   DCBR: 
Dracanea cinnabari  balf  Resin 
 
  
(group 4)showed a significant  effect in decreasing  TC, TG , LDL , and AI. In addition, there 
is no effect on HDL. The last group which was treated with 10 mg /kg Atorvastatin showed 
no effect on TC, TG. But, also showed a significant increase in HDL and no significant effect 
on VLDL and AI.   
 
 
  
Table (6):  Effects of DCBR extract on the lipid profile mg/dl of high fat diet hyperlipidemic rats after 14 days; n=6. 
Groups TC 
 
TG HDL LDL VLDL AI 
Group 1 59.2±13.51 
 
103.98±20.5 52.48±5.83 73.5±14.54 20.79±4.1 1.13±0.25 
Group 2 111.5±9.31* 136±2.19* 28±1.09* 130.5±7.12* 27.2±0.43* 3.97±0.17* 
Group 3 93.46±9.98** 107±8.19** 36±3.89** 119.66±12.2 21.4±1.63** 2.63±0.51** 
Group 4 77.01±8.84** 96.08±23.61** 28±0.63 102.16±4.75** 19.21±4.72** 2.74±0.28** 
Group 5 113.05±11.83 134±3.63 37.5±3.27** 121±10.31 26.8±0.72 3.02±0.28** 
Values are expressed as Mean ±SD; *P ≤ 0.05 vs. group 1, **P ≤ 0.05  vs. group 2. DCBR: Dracanea cinnabari balf Resin, TC: Total 
Cholesterol, TG: Triglyceride, HDL: High Density Lipoprotein,  LDL: Low Density Lipoprotein, VLDL: Very Low Density Lipoprotein, 
AI:  Atherogenic  Index.  
  
 
Histopathological examination of liver and Aorta 
 Macroscopic observations : 
The liver was subjected to macroscopic and microscopic investigation to detect irregularities and 
abnormalities of the structure. Macroscopic analysis of the liver in hyperlipidemic group (group 
2) demonstrated major light brown color changes of the liver lobes (Fig.3a, 3b).  While the liver 
of the normal group (group 1) looks in a normal appearance i.e deep brown color with smooth 
surface (Fig.2a).  The hyperlipidemic groups treated with 100mg/kg DC extract (group 3), 300 
mg/kg DC extract (group 4), and 10 mg/kg Atorvastatin (group 5) shown pale brown coloration 
of the hepatic soft tissue (Fig. 4a,4d,4g). In addition, inducing high fat diet shows a clear 
accumulation of fat in the adipose tissue inside the rat abdomen. Which is clear   in group 2 
(Fig3b &3c). The treated group with 100mg/kg DC extract shows no big difference in the 
amount of the accumulation of the fat in adipose tissue (Fig.4b). Whereas other doses of 300 
mg/kg DC extract and 10 mg/kg Atorvastatin shows a notable decrease Fig. 4. 
 Microscopic observations : 
 The normal liver tissue section of group 1 shows normal structure i.e portal vein, hepatic 
cord, and hepatic sinuside (Fig. 2d).  Whereas the hyperlipidemic rat liver tissue section (group 
2) shows distortion in the arrangement of cells around the central vein, inflammation Fig. 3g, 
infiltration Fig3i, fatty changes Fig. 3d, hemorrhage Fig. 3e, hydropic change Fig. 3f, 
vasodilation Fig.3h. The hyperlipidemic groups treated with 100 mg/kg DC extract (group3), 300 
mg/kg DC extract (group4) and 10 mg/kg Atorvastatin ( Group5)  brought back the cellular 
arrangement around the  vein in some parts of the tissue that lead to bring the blood 
vessels  to  the normal  conditions  (Fig. 4c, 4f, 4i respectively). Histopathological picture of 
Aorta all groups does not show any abnormalities Fig. (5). 
DISCUSSION: 
Alloxan can induce diabetes by destruction of the beta cells of the islets of Langerhans 
of the pancreas [29]. This results in a decrease of endogenous insulin secretion which paves way 
for the decreased utilization of glucose by body tissues and consequently elevation of blood 
glucose level [30]. In current study and after alloxan injection, elevation of blood glucose was 
observed in group 2,3,4 and 5.  When treated them with the ethanolic extract of D 
Cinnabari  it was indicated that all of them reduced the blood glucose level to an extent. The 
dose 100 mg/kg  decreased FBG significantly (p≤ 0.05) up to 24 % and 53 % after 7, 14 day 
respectively. Also, the dose 300 mg/kg showed more decrease in FBG significantly (p≤ 0.05) up 
to 60.5 % and79 % after 7 and 14 days respectively. These results were compatible with [31] 
[23]. 
Chen et.al., 2013 demonstrated hypoglycemic effect of total flavonoids of Dracaena 
cochinchinensis in type 2 diabetes mellitus rats [31]. Also, Gu et al., 2009 showed an antidiabetic 
effect of Dracaena Cochinchinensis by inhibition on alpha-glucosidase activity and suppressing 
intestinal carbohydrate absorption and thereby reducing the postprandial increase of blood 
glucose [23]. In a vitro study reported the ethyl acetate extract of  Dragon cinnabari resin has 
antidiabetic properties with standard Glucose uptake procedure against MCF-7 cell line [19]. 
The mechanism of antidiabetic properties of the extract is not well known. But, it is 
returned likely to the phytochemical constituents including flavonoids, alkaloids, tannins, and 
others. Theses constitutes also  obtained from various plant sources and they have been reported 
to be potent hypoglycemic agents [32]. 
  
 
Flavonoids are the main chemical constituents of dracaena species [33][31][34]. 
Numerous studies have been approved the potential role of flavonoids as antidiabetic, 
antihyperlipidemic and antioxidant [35] [36][37]. Dracaena cochinchinensis extract, a Chinese 
traditional dragon blood plant, has shown to possess antidiabetic as well as antihyperlipidemic 
properties in earlier studies [34]  
Flavonoids derivative from  the methanoilc extract of  Origanum majorana L.(family: 
Lamiaceae) leaves have α-glucosidase enzyme inhibitory activity [38]. Another flavonoids from 
Cecropia obtusifolia (family: Ceropiaceae) exhibited potent hypoglycemic activity comparable 
to that of glibenclamide at a dose of 3 mg/kg in diabetic rats [39]. Other flavonoids were isolated 
from the dried leaves of Myrcia multiflora DC. (family: Myrtaceae) inhibited the activity of  the 
rat  lens aldose reductase enzyme so decrease diabetic complications [40].  
Flavonoids isolated from Eysenhardtia platycarpa (family: Leguminosae) were 
evaluated to possess promising anti-hyperglycemic activity by decreasing  glucose level of 
streptozotocin (STZ)- induced diabetic rats (31 mg/kg of body weight, P < 0.05) [41]. In 
addition, leaves of Eucommia ulmoides (family: Eucommiaceae) has flavonoid which inhibit 
glycation end-product formation, one of main molecular mechanisms implicated in diabetic 
complications [42]. 
Flavonoids can decrease the blood glucose by pancreatic and extra pancreatic 
mechanisms. They can act as insulin  secretagogues  which increase insulin secretion in vitro and 
in vivo systems [43][38]. in similar to Sulfonylureas such as glibenclamide [44] which was used 
as the reference drug in this study. They also can inhibit α-glucosidase activity in the intestine 
and reduce glucose absorption from intestine [23].  
There are convincing experimental and clinical evidence that the generation of ROS is 
increased in both Type 1 and Type 2 diabetes and that the onset of diabetes is closely associated 
with oxidative stress [45]. Flavonoids are rich in phenol groups which work as antioxidant which 
may have slowed or terminated the production of ROS thereby reversing the diabetic condition 
[17] [46][47] [48].  
In the histopathology, the degeneration observed in the pancreas of alloxan-induced 
diabetic rats may be due to necrotic action of alloxan on the beta cells [49] [50]. The 
degenerative changes induced by alloxan in rats pancreas were recovered by DCBR extract and 
glibenclamide which was followed by regeneration of the islet cells and increased tissue density 
with attendant improved insulin production and reduction of FBG in rats. This effect was more 
pronounced at 300 mg/kg DCBR extract. It has been demonstrated that beta cells can regenerate 
from stem cells located in pancreatic ducts or from progenitor cells residing inside murine islets 
[51]. Regeneration of the islet cells by DCBR extract may involve promotion of the above 
mechanisms. Also, Flavonoids are reported to regenerate the damaged pancreatic β - cells in 
diabetic animals  which were acting as antioxidant  and reducing the cells damage by alloxan 
[52].  
Furthermore, the current study showed antihyperlipidemic effect of DCBR extract 
which is agreed with Fan et al. 2014 [34]. High fat diet administered to rats raised the lipid 
profile and with treatment by extract, lipids are decreased by 16%, 31% TC.21%,29% TG. 8%, 
22% LDL. 21%, 29% VLDL with 100 mg/kg and 300 mg/kg respectively. and decrease 
athereogenic index which is an indicator to decrease the atherosclerosis risks. Increase HDL to 
25% with 100 mg/kg dose with no effect with the dose 300 mg/kg. 10 mg/kg of atorvastatin 
which was used as a reference drug did not show effect on  TC and TG. atorvastatin works by 
  
 
inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in 
production of cholesterol in the body. While the outer source of lipid was continuous in food, 
may this interpret the lack effect of atorvastatin. 
Various mechanisms can be explained how flavonoids, which is the main component 
of Dracaena cinnabari, decreased the lipid profile. Hyperlipidemia related to increased oxidative 
stress causing significant production of oxygen free radicals, which may lead to oxidative 
modifications in low-density lipoproteins, which present a significant function in the initiation 
and progression of atherosclerosis and associated cardiovascular diseases [5].Flavonoids can act 
directly as scavenging some radical species, thus acting as  antioxidants and inhibit the 
progression of atherosclerosis [47].  
Flavonoids can  bind with bile acids. since these resin are not absorbed , bile acids are 
excreted.  This results in a decreasing  bile acid uptake by  the liver, and therefore in a higher 
conversion of cholesterol to bile acids in the liver [53].Also, flavonoids can  Inhibit Pancreatic 
cholesterol esterase enzyme ,therefore limit the absorption of dietary cholesterol  [54][55][53] 
4- then reduce the  solubility of cholesterol in micelles which may result in delayed cholesterol 
absorption [56] [54]. The histopathlogical finding of liver showed an enhancement in some parts 
of the tissue, because of the effect of the extract in reducing blood lipid. By the way, long-term 
treatment is required for regeneration the whole tissue. 
In conclusion, ethanolic DCBR extract has demonstrated significant antidiabetic and 
antihyperlipidemic activity. This effect is dose and time dependent.  This effect is may be due to 
the presence of flavonoids in the whole extract, which are working by different mechanisms. 
However, further studies are recommended to isolate and elucidate the bioactive compound(s) 
responsible for its antidiabetic and antihyperlipidemic activity and its molecular mechanism of 
action. 
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